Edition:
United States

Evotec AG (EVTG.DE)

EVTG.DE on Xetra

12.47EUR
26 May 2017
Change (% chg)

€0.01 (+0.12%)
Prev Close
€12.45
Open
€12.45
Day's High
€12.55
Day's Low
€12.36
Volume
541,792
Avg. Vol
1,276,237
52-wk High
€13.47
52-wk Low
€3.10

Latest Key Developments (Source: Significant Developments)

Evotec receives milestone as part of alliance with Bayer
Monday, 22 May 2017 01:29am EDT 

May 22 (Reuters) - Evotec AG :Evotec receives pre-clinical milestone as part of its endometriosis alliance with Bayer.Payment of approx. Eur 5 m to Evotec for transition of a programme into pre-clinical development for treatment of endometriosis.This milestone was achieved under successful strategic alliance between Evotec and Bayer entered in october 2012.  Full Article

Evotec Q1 core profit up 13 pct, guidance affirmed
Wednesday, 10 May 2017 01:33am EDT 

May 10 (Reuters) - Evotec AG :Q1 revenue rose 34 percent to 50.2 million eur.Novo a/s new strategig investor in evotec.Adjusted group EBITDA increased to eur 13.2 m (2016: eur 7.2 m);.Says guidance 2017 confirmed.Strong strategic liquidity position of eur 185.0 m.Source text for Eikon: ID:nEQbR0x2Y.  Full Article

Evotec achieves first milestone in diabetes alliance with Sanofi
Wednesday, 5 Apr 2017 01:29am EDT 

Evotec AG : Says achieves first milestone in diabetes alliance with sanofi .Says triggers a payment of eur 3.0 m to evotec.  Full Article

Evotec sees significant improvement in 2017 core profit
Tuesday, 28 Mar 2017 01:36am EDT 

Evotec Ag : 2016 total group revenues up 29 pct to 164.5 mln eur . 2016 base revenues up 26 pct to 145.6 mln eur . 2016 adjusted group EBITDA increased to 36.2 mln eur . 2016 stable group research and development expenses of 18.1 mln eur . Liquidity position of 126.3 mln eur (2015: 133.9 mln eur) by end of 2016 . Liquidity position further improved in Q1 2017 following 90.3 mln eur capital increase with Novo a/s . Group revenues expected to increase by more than 15 pct in 2017 . Revenue guidance from 2017 onwards based on total group revenues and not on revenues excluding milestones, upfronts and licences . Research and development expenses in 2017 are expected to be approx. 20 mln eur in total and thus similar to 2016 .Adjusted group EBITDA expected to improve significantly in 2017.  Full Article

Evotec says will issue 13.1 million new shares to Novo A/S
Thursday, 9 Feb 2017 03:34pm EST 

Evotec Ag : Novo A/S becomes new long-term strategic shareholder in Evotec . It resolved on a capital increase from its authorised capital against cash . Evotec will issue 13.1 million new shares to Novo A/S .Novo A/S will invest eur 90.3 m to subscribe shares of evotec at a share price of eur 6.87 per share.  Full Article

Evotec confirms its liquidity guidance after Cyprotex acquisition
Thursday, 15 Dec 2016 01:30am EST 

Evotec AG : Says completes acquisition of Cyprotex Plc . Confirms its liquidity guidance for 2016 .It is expected that Cyprotex business will add around 18-20 mln euros in revenues in 2017 and will be accretive to evotec's 2017 EBITDA.  Full Article

Evotec, Forge form strategic "superbug" alliance
Friday, 9 Dec 2016 01:33am EST 

Evotec AG :Says Evotec and Forge Therapeutics form strategic 'superbug' alliance.  Full Article

Evotec plans to acquire Cyprotex for 62 mln eur
Wednesday, 26 Oct 2016 03:00am EDT 

Evotec Ag : Evotec AG announces its intent to acquire Cyprotex plc . Offer is intended to be implemented by a scheme of arrangement regulated by uk takeover code, with already >50% shares secured irrevocable . Offer of 1.60 £ per Cyprotex share reflects a 9.4% premium to vwap of past 30 trading days at AIM .Says Evotec will pay approximately £ 55.36 m (eur 62.00 m; £/eur exchange rate of 1.12) in cash for acquisition of all 26.1 million issued and to be issued cyprotex shares and funding of all existing company debt.  Full Article

Evotec, Carrick Therapeutics agree strategic alliance
Tuesday, 4 Oct 2016 01:29am EDT 

Evotec AG : Evotec and Carrick Therapeutics build strategic alliance . Evotec contributes $6 million to Carrick's $95 million funding round through a top-class global investor consortium .Evotec's financial guidance for 2016, also with regard to liquidity, remains unchanged.  Full Article

Evotec, Bayer to develop new treatments to fight kidney diseases
Wednesday, 21 Sep 2016 01:29am EDT 

Evotec AG : Says goal is development of multiple clinical candidates for treatment of kidney diseases such as chronic kidney disease in diabetes patients . Says partners will share responsibilities during pre-clinical development of potential clinical candidates . Says will receive a minimum of eur 14 m over contract period including research payments and an undisclosed licence fee . Says is eligible to receive pre-clinical, clinical and sales milestones of potentially over eur 300 m as well as tiered royalties of up to low double-digit percentage of net sales .Says evotec and bayer partner to develop new treatments to fight kidney diseases.  Full Article

More From Around the Web

BRIEF-Evotec receives milestone as part of alliance with Bayer

* Evotec receives pre-clinical milestone as part of its endometriosis alliance with Bayer